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Original Investigation | Cardiology

Association Between Baseline Diastolic Blood Pressure and the Efficacy
of Intensive vs Standard Blood Pressure–Lowering Therapy
Andrew J. Foy, MD; Edward J. Filippone, MD; Eric Schaefer, PhD; Matt Nudy, MD; Mohammed Ruzieh, MD; Anne-Marie Dyer, MS;
Vernon M. Chinchilli, PhD; Gerald V. Naccarelli, MD

Abstract
IMPORTANCE Low diastolic blood pressure (DBP) has been found to be associated with increased
adverse cardiovascular events; however, it is unknown whether intensifying blood pressure therapy
in patients with an already low DBP to achieve a lower systolic blood pressure (SBP) target is safe or
effective.

Key Points
Question Is there an interaction
between baseline diastolic blood
pressure and intensification of blood
pressure–lowering therapy for survival
and cardiovascular outcomes?

OBJECTIVE To evaluate whether there is an association of baseline DBP and intensification of blood

Findings In this cohort study of 14 094

pressure–lowering therapy with the outcomes of all-cause death and cardiovascular events.

patients from 2 large randomized clinical
trials, baseline DBP of 80 and 90 mm

DESIGN, SETTING, AND PARTICIPANTS This cohort study analyzed patients who were randomized

Hg were associated with significant

to intensive or standard BP control in the Action to Control Cardiovascular Risk in Diabetes–Blood

reductions in the risk of a composite

Pressure (ACCORD-BP) trial and Systolic Blood Pressure Intervention Trial (SPRINT). Data were

cardiovascular end point that included

collected from September 1999 to June 2009 (ACCORD-BP) and from October 2010 to August 2015

cardiovascular death, nonfatal

(SPRINT). Data were analyzed from December 2020 to June 2021.

myocardial infarction, and nonfatal
stroke. The same was not true for the

EXPOSURES Baseline DBP as a continuous variable.

outcome of all-cause death.
Meaning The findings of this study

MAIN OUTCOMES AND MEASURES All-cause death and a composite cardiovascular end point
(CVE) that included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

suggest that further work is needed to
determine whether blood-pressure
lowering therapy should be intensified

RESULTS A total of 14 094 patients (mean [SD] age, 66.2 [8.9] years; 8504 [60.4%] men) were
included in this analysis. There were significant nonlinear associations between baseline DBP and

in patients whose diastolic blood
pressure is low.

all-cause death (eg, baseline DBP 50 vs 80 mm Hg: hazard ratio [HR], 1.48; 95% CI, 1.06-2.08;
P = .02) and the composite CVE (eg, baseline DBP 50 vs 80 mm Hg: HR, 1.45; 95% CI, 1.27-3.04;
P = .003) observed among all participants. Findings for the interaction between baseline DBP and
treatment group assignment for all cause death did not reach statistical significance. For intensive vs
standard therapy, the HR of death for a baseline DBP of 50 mm Hg was 1.80 (95% CI, 0.95-3.39;

+ Invited Commentary
Author affiliations and article information are
listed at the end of this article.

P = .07) and that for a baseline DBP of 80 mm Hg was 0.77 (95% CI, 0.59-1.01; P = .05). Overall, there
was no interaction found between baseline DBP and treatment group assignment for the composite
CVE. Over the range of baseline DBP values, significant reductions in the composite CVE for patients
assigned to intensive vs standard therapy were found for baseline DBP values of 80 mm Hg (HR,
0.78; 95% CI, 0.62-0.98; P = .03) and 90 mm Hg (HR, 0.74; 95% CI, 0.55-0.98; P = .04).
CONCLUSIONS AND RELEVANCE This pooled cohort study found no evidence of a significant
interaction between baseline DBP and treatment intensity for all-cause death or for a composite CVE.
These results are hypothesis generating and merit further study.
JAMA Network Open. 2021;4(10):e2128980. doi:10.1001/jamanetworkopen.2021.28980
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Introduction
Since the publication of the landmark Systolic Blood Pressure Intervention Trial (SPRINT),1 the focus
in treating hypertension has been on systolic blood pressure (SBP). However, this ignores
observational data showing a J-shaped curve for diastolic blood pressure (DBP), where adverse
cardiovascular events and mortality increase as DBP decreases below critical levels (<60 mm Hg).2-4
It has been postulated that pharmacological treatment to achieve a lower SBP target in persons
whose DBP is already low may worsen patient outcomes. To test this hypothesis, we performed a
pooled cohort analysis combining participants from SPRINT1 with those of the similarly designed
Action to Control Cardiovascular Risk in Diabetes–Blood Pressure (ACCORD-BP) trial5 to assess
whether there is an association between baseline DBP and treatment intensity on patient outcomes.

Methods
This cohort study was reported in adherence with the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline. The study met all criteria for exemption by
the institutional review board at Penn State College of Medicine. Informed consent was waived
because data were deidentified.
The designs and outcomes of ACCORD-BP5 and SPRINT1 have been reported previously, and
patient-level data from each trial were obtained from the Biologic Specimen and Data Repository
Information Coordinating Center of the National Institutes of Health. In brief, ACCORD-BP was a
randomized trial of 4733 patients with diabetes with elevated cardiovascular risk assigned to either
intensive (ie, SBP <120 mm Hg) or standard (ie, SBP <140 mm Hg) BP control and followed for a
median of 4.7 years. SPRINT randomized 9361 patients without diabetes with elevated
cardiovascular risk to either intensive or standard BP control, using the same targets as ACCORD-BP,
and followed them for a median of 3.3 years.

Statistical Analysis
We used a Cox proportional hazards model to test the association between baseline DBP as a
continuous variable and the outcomes of interest. These outcomes were all-cause mortality and a
composite cardiovascular end point (CVE) that included cardiovascular death, nonfatal myocardial
infarction (MI), or nonfatal stroke. This composite CVE was chosen because it was the primary
composite end point of the ACCORD-BP trial and because each of these individual end points was
included in the composite primary end point of the SPRINT trial. The completed analysis included the
following variables measured at baseline: DBP, age, sex, history of MI, history of congestive heart
failure, history of peripheral vascular disease, history of stroke, estimated glomerular filtration rate at
baseline, treatment group (intensive vs nonintensive), stratification factor for study (SPRINT vs
ACCORD-BP), and stratification factor for site. To allow for nonlinear associations with outcomes, we
used a restricted cubic spline with 4 df. The level of significance was set to a 2-sided P < .05, and the
hazard ratios (HRs) and corresponding 95% CIs were reported from these models. We also showed
the association in graphical form using the log hazard scale.
A separate Cox proportional hazards regression model was used to test for an interaction
between baseline DBP as a continuous variable and treatment group assignment. The outcomes
were all-cause mortality and the aforementioned composite CVE. The completed analysis included
all variables used in the model described already but included the additional variable of interaction
between treatment group and DBP. To allow for nonlinear associations with outcomes, we used a
restricted cubic spline with 4 df. The level of significance was set to P < .05, and the HRs and
corresponding 95% CIs were reported from these models. We also showed the associations in
graphical form using the log hazard scale.
For representative purposes, baseline characteristics are presented for all patients stratified by
baseline DBP less than 60 mm Hg and greater than or equal to 60 mm Hg. The change in SBP and
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DBP values from baseline to 12 months is also presented for these DBP subgroups based on
treatment group assignment (intensive vs nonintensive).
Analyses were generated using SAS STAT software version 9.4 for Windows (SAS Institute).
Data were analyzed from December 2020 to June 2021.

Results
The data included 14 094 participants (mean [SD] age, 66.2 [8.92] years; 8504 men [60.3%]), with
4733 (33.6%) coming from ACCORD and 9361 (66.4%) coming from SPRINT. The overall number of
patients who died was 672 (4.8%), and the number experiencing the combined CVE was 893 (6.3%).
More patients died from noncardiovascular causes (392 patients) than cardiovascular causes (280
patients) (Table 1). The median (IQR) baseline DBP was 77 (70-85) mm Hg (Table 1). A distribution
plot of baseline DBP values for all participants is provided in Figure 1. In total, 97 patients (0.7%) had
at least 1 missing baseline value involving comorbid conditions and were excluded when fitting the
models. There were significant associations between baseline DBP (modeled nonlinearly) and
all-cause death (eg, baseline DBP 50 vs 80 mm Hg: HR, 1.48; 95% CI, 1.06-2.08; P = .02; baseline
DBP 110 vs 80 mm Hg: HR, 2.15; 95% CI, 1.30-3.56; P = .003) and the composite CVE (eg, baseline
DBP 50 vs 80 mm Hg: HR, 1.45; 95% CI, 1.27-3.04; P = .003; baseline DPB 110 vs 80 mm Hg: HR,
1.96; 95% CI, 1.27-3.04; P = .003). The resulting estimated associations were U-shaped (Figure 2).
When analyzed as a continuous variable, findings for the association between baseline DBP and
treatment group assignment for the outcome of all-cause death did not reach statistical significance
(Figure 2). No interaction was seen between baseline DBP and treatment group for the composite
CVE (Figure 2). HRs and corresponding P values from the Cox model are provided in Table 2 for
intensive vs standard groups.
For intensive vs standard therapy, for a baseline DBP of 50 mm Hg, the HR of death was 1.80
(95% CI, 0.95-3.39; P = .07); for 60 mm Hg, the HR was 1.12 (95% CI, 0.84-1.50; P = .43); for 70 mm
Hg, the HR was 0.82 (95% CI, 0.65-1.02; P = .08); for 80 mm Hg, the HR was 0.77 (95% CI, 0.59-1.01;
P = .05); for 90 mm Hg, the HR was 0.85 (95% CI, 0.59-1.20; P = .35), for 100 mg Hg, the HR was

Table 1. Baseline Characteristics Stratified by Study
Participants, No. (%)
Characteristic

ACCORD-BP (n = 4733)

SPRINT (n = 9361)

Total (N = 14 094)

Age at baseline, y
Mean (SD)

62.7 (6.68)

67.9 (9.40)

66.2 (8.92)

Median (IQR) [range]

62.0 (57.6-67.0)
[44.4-79.3]

67.0 (61.0-75.0)
[46.0-90.0]

65.0 (59.0-73.0)
[44.4-90.0]

Male

2475 (52.3)

6029 (64.4)

8504 (60.3)

Female

2258 (47.7)

3332 (35.6)

5590 (39.7)

Participants, No.

4731

9346

14 077

Mean (SD)

76.0 (10.39)

78.1 (11.95)

77.4 (11.49)

Median (IQR) [range]

76.0 (69.0-83.0)
[38.0-118.0]

78.0 (70.0-86.0)
[40.0-134.0]

77.0 (70.0-85.0)
[38.0-134.0]

Sex

Diastolic blood pressure, mm Hg

Congestive heart failure

203 (4.3)

326 (3.5)

529 (3.8)

Peripheral vascular disease

160 (3.4)

503 (5.4)

663 (4.7)

Stroke

307 (6.5)

48 (0.5)

355 (2.5)

Participants, No.

4714

9307

14 021

Mean (SD)

91.6 (28.75)

71.8 (20.60)

78.4 (25.45)

Median (IQR) [range]

89.7 (75.5-105.8)
[15.3-852.7]

71.4 (58.1-84.7)
[14.7-186.2]

77.0 (62.6-91.3)
[14.7-852.7]

Estimated glomerular filtration rate,
mL/min/1.73 m2
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0.79 (95% CI, 0.48-1.28; P = .34); for 110 mm Hg, the HR was 0.64 (95% CI, 0.25-1.64; P = .35)
(Table 2). For intensive vs standard therapy, significant reductions in the composite CVE were found
for DBP values of 80 mm Hg (HR, 0.78; 95% CI, 0.62-0.98; P = .03) and 90 mm Hg (HR, 0.74; 95%
CI, 0.55-0.98; P = .04) (Table 2).

Figure 1. Histogram of Baseline Diastolic Blood Pressure Values
Among Participants of the Action to Control Cardiovascular Risk
in Diabetes–Blood Pressure and Systolic Blood Pressure Intervention
Trial Trials
1000
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Figure 2. Log Hazard Plots of Baseline Diastolic Blood Pressure and All-Cause Death and the Composite Cardiovascular End Point
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Log hazard plots of the baseline DBP and all-cause mortality and baseline DBP and the composite cardiovascular end point are shown overall (A and B) and according to treatment
group assignment (C and D). Shaded areas in A and B denote 95% CIs.
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There were 800 participants with baseline DBP less than 60 mm Hg and 13 277 with baseline
DBP greater than or equal to 60 mm Hg. Individuals with baseline DBP less than 60 mm Hg were
older (mean [SD] age, 73.6 [8.7] vs 65.7 [8.7] years) and had 3-fold higher risk of dying (74 patients
[9.3%] vs 598 patients [4.5%]) than those with baseline DBP greater than or equal to 60 mm Hg
(Table 3). Baseline SBP and DBP values were similar for those assigned to intensive vs standard
control at baseline in both subgroups; however, by 12 months there were significant differences in
achieved levels (Table 3). For individuals with baseline DBP less than 60 mm Hg, the mean (SD) SBP
and DBP values at 12 months for the intensive and standard therapy groups were 122.4 (14.9) and
56.3 (9.0) mm Hg and 134.2 (14.9) and 62.4 (9.6) mm Hg, respectively. For those with baseline DBP
greater than or equal to 60 mm Hg, the mean (SD) SBP and DBP values at 12 months for the intensive
and standard therapy groups were 121.0 (13.8) and 68.8 (9.6) mm Hg and 135.6 (13.7) and 76.0 (10.4)
mm Hg, respectively.

Discussion
In this pooled cohort analysis of patients from the ACCORD-BP and SPRINT trials, we tested the
association between baseline DBP and patient outcomes. We also tested for an association between
baseline DBP and treatment group assignment with respect to patient outcomes. Our results confirm
prior observations of a nonlinear association between DBP and patient outcomes that appears
U-shaped. No statistically significant interactions were observed, however, with respect to DBP and
treatment group assignment for all-cause mortality or the composite CVE. This undermines the
traditional J-curve hypothesis relating low DBP with reduced coronary perfusion and events.
Although we acknowledge our findings do not establish the existence of an interaction between
baseline DBP and treatment group assignment for the outcome of all-cause death, we think it would
be imprudent to dismiss possible associations altogether. Treatment effect heterogeneity emerges
from a few essential risk dimensions, including (1) the risk of the primary study outcome, (2)
competing risk, (3) the risk of treatment-related harm, and (4) direct treatment-effect
modification.6-8 In individuals with lower baseline DBP values, factors unrelated to blood pressure
may be associated with death more so than for individuals with higher DBP. Patients whose baseline
DBP was less than 60 mm Hg compared with those with higher values were at 3-fold higher risk of
dying (9% vs 3%), were significantly older (73.6 vs 65.7 years), and had higher rates of all comorbid
conditions (Table 3). It is also not implausible to speculate that such individuals would be at increased
risk of treatment-related harm, both measured and unmeasured and that they would not recover the
same from adverse events as healthier subjects (adverse events were significantly increased in
ACCORD-BP and SPRINT in the intensive therapy groups), and finally, that lowering blood pressure
would not yield the same benefits as in those generally healthier subjects. A limitation of this analysis
is that it did not look at serious adverse events in relation to baseline DBP, but this was intentional

Table 2. Estimated HRs From Cox Models for All-Cause Mortality and the Composite Cardiovascular End Point
When Baseline DBP Is Treated as a Continuous Variable
DBP by treatment interaction,
intensive vs nonintensive, mm Hg

All-cause mortality

Composite cardiovascular end point

HR (95% CI)

P value

HR (95% CI)

Overall

Not applicable

.13

Not applicable

.88

50

1.80 (0.95-3.39)

.07

0.77 (0.44-1.33)

.35

60

1.12 (0.84-1.50)

.43

0.85 (0.66-1.10)

.22

70

0.82 (0.65-1.02)

.08

0.85 (0.69-1.03)

.10

80

0.77 (0.59-1.01)

.05

0.78 (0.62-0.98)

.03

90

0.85 (0.59-1.20)

.35

0.74 (0.55-0.98)

.04

100

0.79 (0.48-1.28)

.34

0.67 (0.45-1.01)

.05

110

0.64 (0.25-1.64)

.35

0.60 (0.26-1.37)

.22
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owing to the different definitions and adjudication procedures used for defining these events within
the trials.
The notion of treatment effect heterogeneity for common interventions in high-risk patients is
not unprecedented in cardiovascular medicine. An example of this within an individual trial can be
found in the Sudden Cardiac Death in Heart Failure Trial,9 where there was a significant association of
heart failure class and implantable cardioverter-defibrillator therapy with mortality. Patients with
New York Heart Association class III heart failure derived no benefit from implantable cardioverterdefibrillator therapy but those with New York Heart Association class II heart failure benefited
greatly. The 5-year mortality rates in the New York Heart Association classes III and II placebo groups
were 46% and 32%, respectively.9 This same dynamic can be seen across trials as well. In the Study
to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis trial,10 a high-risk population
of dialysis patients derived no benefit from statin therapy. The rates of death and nonfatal MI in the
control group of this population were 14 per 100 person-years and 2.5 per 100 person-years,
respectively.10 Contrary to this, in the Justification for the Use of Statins in Prevention: An
International Trial Evaluating Rosuvastatin trial,11 a much lower risk population of patients who were

Table 3. Baseline Characteristics of Individuals With Baseline DBP Less Than and Greater Than
or Equal to 60 mm Hg Along With Blood Pressure Control at Baseline and 12 Months
Participants, No. (%)
Variable

DBP <60 mm Hg (n = 800)

DBP ≥60 mm Hg (n = 13 277)

Mean (SD)

73.6 (8.7)

65.7 (8.7)

<50

0

111 (0.8)

50-59

68 (8.5)

3629 (27.3)

60-69

183 (22.9)

5379 (40.5)

70-79

343 (42.9)

3210 (24.2)

≥80

206 (25.8)

948 (7.1)

Male

472 (59.0)

8026 (60.5)

Female

328 (41.0)

5251 (39.5)

Myocardial infarction

115 (14.4)

1295 (9.8)

Congestive heart failure

46 (5.8)

483 (3.6)

Peripheral vascular disease

88 (11.0)

575 (4.3)

Stroke

29 (3.6)

326 (2.5)

Estimated glomerular filtration rate,
mean (SD), mL/min/1.73 m2

68.4 (23.7)

79.0 (25.4)

Uncomplicated

94 (11.8)

2118 (16.0)

End-organ damage

167 (20.9)

2352 (17.7)

Age, y

Sex

Diabetes

BP control, mean (SD), mm Hg
Baseline
SBP
Intensive therapy

127.0 (15.4)

140.2 (15.6)

Standard therapy

128.1 (15.7)

140.3 (15.1)

DBP
Intensive therapy

54.9 (3.8)

78.8 (10.4)

Standard therapy

55.2 (3.7)

78.7 (10.3)

12 mo
SBP
Intensive therapy

122.4 (14.9)

121.0 (13.8)

Standard therapy

134.2 (14.9)

135.6 (13.7)

DBP
Intensive therapy

56.3 (9.0)

68.8 (9.6)

Standard therapy

62.4 (9.6)

76.0 (10.4)
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in generally good health derived a significant benefit from statin therapy. The same rates of death and
nonfatal MI in the control group of this population were 1.25 per 100 person-years and 0.33 per 100
person-years, respectively.11
In the recently published International Study of Comparative Health Effectiveness with Medical
and Invasive Approaches-Chronic Kidney Disease trial,12,13 patients with advanced chronic kidney
disease derived no benefit from an invasive compared with conservative strategy and were more
likely to experience a stroke or a composite of death from any cause or initiation of dialysis. The
3-year rates of death and nonfatal MI in the control group of this population were 27.8% and 15.9%,
respectively.12,13 In the main trial,14,15 which excluded CKD patients with chronic kidney disease, fewer
events were experienced in the invasive group, and there was a significant reduction in angina and
no evidence of harm. The 3-year rates of death and nonfatal MI in the control group of this population
were 4.3% and 8.5%, respectively.14,15
Our study is not the first to look for an interaction between intensive therapy and baseline DBP
in an intention-to-treat fashion. In a reanalysis of SPRINT-only patients, Beddhu et al16 did not find
an interaction between baseline DBP and all-cause death, the composite CVE, or chronic kidney
disease events when DBP subgroups were analyzed on the basis of quintiles, or when the lowest
quintile was compared with the remaining cohort. There are several notable differences between this
study16 and ours. First, the use of SPRINT-only patients would reduce power to detect any subgroup
interactions, if present. Second, their method only considered baseline DBP as a dichotomous
variable (based on quintiles) and in doing so, they included many patients with DBPs much greater
than 60 mm Hg in their lowest quintile (the mean [SD] DBP of this group was 61 [5] mm Hg).16 Our
analysis of DBP as a continuous variable suggests the interaction occurs very near the 60 mm Hg
mark. Finally, in their analysis they do report a P value for the interaction between baseline DBP and
treatment intensity on all-cause death of .29.16 Although this is far from the traditional bounds of
what is considered statistically significant, it may not be trivial. P values for testing interactions may
be considered hypothesis-generating at lower thresholds than the 95% mark used for hypothesis
testing and confirmation.
Li and colleagues17 studied the association between DBP and outcomes for patients in the
ACCORD-BP and SPRINT trials among patients who achieved a SBP less than 130 mm Hg. Among
such patients, those with treated DBP lower than 60 mm Hg had higher rates of events. Their
findings are consistent with our study and many others in the past that have looked at baseline and
achieved DBP levels and found associations between lower values and outcomes. We did this by
looking at baseline DBP as a continuous variable and found significant nonlinear associations with
all-cause death and a composite CVE among patients in the ACCORD-BP and SPRINT trials (Figure 2).
However, these observations in themselves do not directly address the question of whether starting
or intensifying therapy in patients with DBP values less than a certain number to achieve a lower SBP
target is effective or not. To the best of our knowledge, only this study and the one by Beddhu et al16
address this question directly.
It should not be construed from our data or the other studies mentioned here that patients with
low DBP should have deintensification of therapy with the aim of increasing DBP. The question
addressed by our study is whether therapy can be safely intensified to lower SBP in such patients.

Strengths and Limitations
Our study has both strengths and limitations. The main strength is the use of individual patient data
from 2 large, randomized clinical trials conducted in the same manner, including both patients with
and without diabetes. Limitations include the lack of a significant number of patients with stroke at
baseline and the low number of patients whose baseline DBP was less than 60 mm Hg.
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Conclusions
In conclusion, this pooled cohort analysis of patients enrolled in the ACCORD-BP and SPRINT trials
supports the existence of a nonlinear association between baseline DBP and patient outcomes as
previously reported. More importantly, it suggests that among patients whose baseline DBP was
greater than 60 mm Hg, intensifying therapy to achieve an SBP target of 120 mm Hg could reduce
death and cardiovascular events. It does not allow us to conclude the same for patients whose
baseline DBP is 60 mm Hg or below since intensifying therapy may not reduce the risk of dying and
could possibly increase it. This topic merits further investigation.
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